in which tumour-cell populations undergo evolutionary change, guided by realistic parameters. The authors used this model to study the growth laws of 3D in silico tumours, focusing on the tumours' geometry and cellular composition. If the tumour cells are relatively immobile, then, as they proliferate and form a malignant mass, they crowd each other out and thus slow their own replication. Soon the tumour can grow only at its surface, which results in a relatively slow expansion (the mass grows as a cubic power of time).
But this slow growth cannot account for the relatively fast tumour expansion observed in many clinical studies. The resolution of this apparent paradox lies in cellular motility. By giving each cell in the model the ability to migrate, the researchers observed a much faster, exponential, growth, which also yielded a different, more realistic, tumour shape ( Fig. 1 ). This result is consistent with the earlier proposition 2 that migratory potential is a component of a cell's evolutionary fitness, in much the same way as is its replicative potential. However, it was previously thought that cell migration was mostly involved in the invasion of tissues by tumours or in metastasis. The direct, pivotal role of cell motility in tumour growth was under-appreciated and can now be considered a valid treatment target.
Another focus of the authors' study was tumour composition. In particular, they asked how quickly a particular mutation can propagate in a mass of cancer cells, thus changing the tumour's properties. Evolutionary processes and their outcomes are largely shaped by the environment in which they take place. For example, evolution in a wellmixed, homogeneous medium takes place at a different pace from evolution in an environment in which interactions are restricted by geometric constraints. And in the latter case, dimensionality is key. For example, it has been shown that inactivation of a tumoursuppressor gene (a two-hit evolutionary process in which the cells must first become less fit before becoming more fit) happens faster in 1D (a row of cells) 3, 4 than in 2D (a layer), and this is in turn faster than in a fully mixed system with no spatial constraints [4] [5] [6] [7] . By contrast, in two-step processes in which the intermediate mutant confers a slight selective advantage, the relationship is the opposite, and a non-spatial, fully mixed environment promotes the fastest pace of evolution 5 . These phenomena seem less surprising if one notes how reminiscent they are of other fundamental laws of nature in which space dimensionality changes how things work, such as the different fundamental solutions of Poisson's equations in 1D and 2D.
Waclaw et al. then set out to understand why, given the high overall degree of tumour heterogeneity, some mutations are so prevalent among the cells of a given tumour. In the context of tumour progression, two broad classes of mutation have been identified 8 . Cells with driver mutations are characterized by having a growth advantage over other cells, and such mutations are thought to be responsible for cancer initiation and progression. Passenger mutations are genomic changes that do not really alter the cells' growth properties, and do not have a causal role in cancer origin or progression. Waclaw and colleagues show that, in the presence of even a small amount of selective advantage (that is, a driver mutation), the affected cells sweep rapidly through a 3D cell population. This explains the observed composition of large tumours, in which almost every cell contains the same driver mutations, and heterogeneity resulting from passenger mutations accumulates later, during tumour progression.
This idea is crucial in the context of cancer therapy. A mutation that confers resistance to a drug is usually a passenger mutation before treatment; such mutations are 'hiding' inside any tumour and are generated simply by chance as a result of the constant background mutation rate. But resistant mutants immediately gain a selective advantage once treatment is applied. Waclaw and colleagues' paper illustrates how rapidly resistant cells can accumulate, leading to regrowth and treatment failure. This happens even faster in the presence of mutations that increase cellular motility.
How far are we from being able to use evolution to our advantage? Understanding evolution's intricate ways brings us a step closer to being able to reverse malignant processes, and to channel the dynamics in the direction we want. And can we use the genes responsible for cell motility or cell adhesion as targets in future cancer treatments? Waclaw and colleagues' theoretical study suggests that this is a possibility, and it is to be hoped that others will take up the challenge. ■ Natalia L. Komarova 
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Mutant p53 and chromatin regulation
The finding that genes encoding enzymes that modify histone proteins are among the targets of certain mutant forms of the p53 protein sheds light on how these mutations cause cancer beyond p53 inactivation. See Article p.206
C A R O L P R I V E S & S C O T T W. L O W E
M utations in the TP53 tumoursuppressor gene are common in human tumours. Although these mutations invariably inactivate the normal activity of p53 (ref. 1) , which is the transcription factor encoded by TP53, some mutations also endow p53 with 'gain-of-function' activities that promote cancer 2 . Whether diverse p53 mutants produce similar gain-of-function activities and how they do so remains a puzzle, but finding the answer might enable the design of strategies for treating many cancers. On page 206 of this issue, Zhu et al. 3 provide a possible explanation: they show that gain-of-function mutant p53 proteins induce the production of enzymes that modify the histone proteins around which DNA is packaged as chromatin, thus altering gene expression.
Experimentally altering the expression of gain-of-function mutant p53 affects the expression of myriad genes, enhancing the invasiveness and proliferation of tumour cells in vitro 4 . Moreover, mice harbouring key gain-of-function mutations in TP53 develop tumours that differ from those lacking p53 (ref. 5) . Lowering the level of gain-of-function p53 has antiproliferative effects in vitro and can reduce metastasis or trigger tumour regression in vivo 2, 5, 6 . A better understanding of these mutants is therefore desirable. Zhu et al. found that, in cultured human-cancer cell lines, gain-of-function mutant forms of p53 bind to different regions of DNA from the normal protein. In particular, the mutant proteins bind to the genes MLL1 and MLL2. Gain-of-function p53 seems to be recruited to whether or when gain-of-function p53 can trigger changes in MLL and MOZ expression, and to analyse the mechanisms underlying these events.
Gain-of-function p53 was also recently shown 11 to act with the SWI/SNF chromatinremodelling complex to upregulate many genes that can themselves mediate the cancercausing activities of gain-of-function p53. This finding, taken together with Zhu and colleagues' demonstration that this p53 is linked to chromatin and, by extension, to the transcriptome (the complete gene-expression profile of the cell), could explain why so many genes are affected by the presence of gain-offunction p53. But precisely how p53 proteins with diverse mutations acquire similar capabilities remains to be discovered.
One possibility is that p53 mutants adopt a different structure from normal p53 that enables their interaction with ETS2. However, there is no obvious explanation for the evolution of such an interaction, and this model is at odds with the observation 12 that some gain-of-function p53 proteins have similar structures to normal p53. Alternatively, the ability of normal p53 to bind to thousands of sites in the human genome might prevent it from associating with the factors with which gain-of-function p53 interacts. Or perhaps the expression of one or more target genes somehow actively prevents the normal protein from engaging in the interactions that are characteristic of the mutant p53.
The authors' link between gain-of-function p53 and MLL1 and MLL2 is intriguing, given that members of the MLL family are frequently mutated in human cancers 13 . For example, chromosomal translocations involving MLL1 can drive leukaemia, and MLL2 mutations are common in several carcinomas. But MLL1 translocations eliminate the gene's histone methyltransferase domain, and MLL2 mutations seem to be inactivating. The explanation for this apparent discrepancy with Zhu and colleagues' findings is unclear, but probably reflects context-dependent differences in enzyme function.
Could targeting MLL1, MLL2 or MOZ be a strategy for treating tumours involving gainof-function p53? Zhu et al. showed that two inhibitors of MLL-complex formation block proliferation in cells expressing mutant p53, but do not affect those lacking p53. Eliminating gain-of-function p53 or interfering with its mechanism of action can have anticancer effects in vitro and in mice 6, 14, 15 . Moreover, there is much enthusiasm for cancer treatments that affect chromatin modification, and compounds that target some chromatinmodifying activities have been approved for use in the clinic or are currently in clinical trials. But more work is required, because the specificity of the MLL inhibitors is not entirely established. Furthermore, MLL genes are active during embryonic development, and their inhibition can cause embryonic death, independent of TP53 mutations 14 . These observations, together with the previously mentioned fact that mutations disrupting MLL function are common in tumours, raise concerns that MLL inhibitors might be toxic, or might even promote tumours.
Nonetheless, given the frequency with which TP53 is mutated in cancer, continued efforts to modulate the effects of mutant p53 are clearly warranted. With the key targets of MLL and MOZ in hand, specific therapies might become possible. Thus, Zhu and colleagues' study, and those of others, might point to treatments for tumours that harbour TP53 mutations. ■ 
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